GlassScriptPhysician profile
Thomas J Robertson
NPI 1154382612
$3,112.71
in general payments reported to CMS, 2019-2025
25 companies · $549 in 2025
The $549 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2020: $415 · 2021: $182 · 2022: $472 · 2023: $611 · 2024: $353 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,511.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,141.87 | 2019-2025 | Rocklatan, Clareon, Centurion |
| Kala Pharmaceuticals, INC. | $302.05 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $293.98 | 2019-2021 | |
| Biotissue Holdings INC. | $237.67 | 2023 | |
| Allergan, INC. | $139.98 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $120.86 | 2019-2021 | |
| Abbvie INC. | $118.16 | 2022-2024 | Alphagan P, Lumigan |
| Bausch & Lomb Americas INC. | $114.35 | 2022-2025 | Envista Envy Iol, Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $111.62 | 2019-2022 | |
| Thea Pharma INC. | $83.88 | 2022-2025 | Iyuzeh |
| Oyster Point Pharma, INC. | $75.19 | 2022-2023 | Tyrvaya |
| Ocular Therapeutix, INC. | $50.08 | 2024-2025 | Dextenza |
| Tarsus Pharmaceuticals, INC. | $48.39 | 2024-2025 | Xdemvy |
| Amgen INC. | $37.77 | 2025 | Tepezza |
| Eyevance Pharmaceuticals LLC | $37.27 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $36.79 | 2022-2025 | Sion Surgical Instrument, Omni Surgical System |
| Akorn, INC. | $31.36 | 2019 | |
| New World Medical,INC. | $20.16 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Horizon Therapeutics Plc | $18.62 | 2023 | Tepezza |
| Tearlab Corp | $17.45 | 2022 | |
| Rayner Intraocular Lenses Limited | $16.29 | 2025 | Omidria |
| Dompe US, INC. | $14.65 | 2019 | |
| Ivantis, INC | $13.22 | 2020 | |
| Shire North American Group INC | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Robertson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.